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Allergic asthma is a chronic, complex inflammatory disease of the airway. Despite extensive studies on 
the immunomodulation of T helper (Th) cell pathways (i.e., Th1 and Th2) in asthma, little is known about 
the effects of Th17 pathway modulation, particularly that involving peroxisome proliferator-activated 
receptors (PPARs). In response, two new thiazolidinedione derivatives—namely, LPSF–GQ-147 and 
LPSF–CR-35 were synthesized and evaluated for their immunomodulatory effects on Th17-related 
cytokines, including interferon γ (IFNγ), interleukin IL-6, IL-17, and IL-22 in the peripheral blood 
mononuclear cells of asthmatic children. Both compounds were nontoxic even at high concentrations 
(i.e., 100 µM). The LPSF–CR-35 compound significantly reduced the levels of IL-17A (p = .039) and 
IFNγ (p = .032) at 10 µM. For IL-22 and IL-6, significant reduction occurred at 100 µM (p = .039 
and p = .02, respectively). Conversely, LPSF–GQ-147 did not significantly inhibit the production of 
the tested cytokines, the levels of all of which were more efficiently reduced by LPSF–CR-35 than 
methylprednisolone, the standard compound. Real-time polymerase chain reaction assay confirmed that 
LPSF–GQ-147 has significant PPARγ modulatory activity. Such data indicate that both LPSF–CR-35 
and LPSF–GQ-147 are promising candidates as drugs for treating inflammation and asthma.
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INTRODUCTION
Asthma is a chronic, complex inflammatory disease 
of the airway whose development requires many cells 
and their products, including mast cells, eosinophils, T 
lymphocytes, macrophages, neutrophils, and epithelial 
cells (Langier, Sade, Kivity, 2012; Robinson, 2009). 
Regarding lymphocytes, the imbalance of T helper (Th) 
cells Th1 and Th2 has been relatively well characterized 
as a mechanism involved in the pathogenesis of allergic 
asthma (Colavita, Reinach, Peters, 2000; Gibeon, 
Menzies-Gow, 2012; Oboki et al., 2008). By contrast, 
the role of the Th17 pathway as a novel proinflammatory 
CD4+ T effector cell in asthma etiology remains largely 
unclear (Cosmi et al., 2011).
In asthma, interleukin (IL)-17 performs its role in a 
crescent area of intense activity. Wong et al. (2009) have 
shown that asthmatic individuals have higher amounts 
of peripheral Th17 cells, CCR6 expression, and IL-23 
and IL-22 production stimulated by peripheral blood 
mononuclear cells (PBMCs) than individuals without 
asthma. In this pathway, IL-6 and transforming growth 
factor beta (TGF- β) together induce the differentiation 
of naïve T cells into Th17 lymphocytes by activating 
transcription factor regulator and thereby becoming 
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producers of IL-17A, IL-17F, IL-22, and IL-23, which are 
responsible for maintaining the Th17 phenotype (Ivanov et 
al., 2006). Although the Th17 pathway mediates protective 
actions in bacterial and fungal infections, in human 
autoimmune and inflammatory diseases it has deleterious 
effects that compromise individual’s clinical evolution 
and is thus an outstanding target for experimental research 
(Korn et al., 2009; Weaver et al., 2007).
A possible  therapeut ic  means to  decrease 
proinflammatory cytokines involved in respiratory 
inflammatory diseases such as asthma is the modulation 
of immunoregulatory proteins such as peroxisome 
proliferator-activated receptor γ (PPARγ) (Amato, Neves, 
2012). Peroxisome proliferator-activated receptors 
(PPARs) are a family of ligand-activated transcription 
factors in the nuclear hormone receptor family and are 
related to retinoid, glucocorticoid, and thyroid hormone 
receptors (Montagner et al., 2011). PPARγ, the most 
extensively studied PPAR subtype, is involved in several 
lung diseases, including lung fibrosis, pulmonary vascular 
diseases, acute lung injury, and lung cancer (Rabinovitch, 
2010). PPARγ activation reduces the synthesis and 
release of immunomodulatory cytokines from many 
cell types, including macrophages and monocytes, 
that participate in the regulation of inflammatory and 
immune processes (Zenhom et al., 2011). Recently found 
evidence suggests that PPARγ plays important roles in 
regulating processes related to airway inflammation, 
airway remodeling, and airway hyper-responsiveness, 
which indicates that it and its ligand show potential for 
developing treatments for chronic airway inflammatory 
diseases (Shen et al., 2012). Thiazolidine-2,4-dione 
(TZD) is a well-characterized synthetic ring that acts 
as a PPARγ agonist and whose structure is responsible 
for most of its pharmacological effects, including anti-
inflammatory ones (Faine et al., 2011). In response, the 
anti-inflammatory properties of new synthesized TZDs 
called LPSF–CR-35 (3-(4-bromo-benzyl)-5-(3-bromo-
benzylidene)-thiazolidine-2,4-dione) and LPSF–GQ-147 
(5-(4-chlorobenzylidene)-3-(3,4-dichlorobenzyl)-
thiazolidine-2,4-dione) were evaluated in PBMCs from 
pediatric asthmatic individuals, particularly regarding 
their immunomodulatory effect on Th17 pathway-related 
cytokines.
MATERIAL AND METHODS
Synthesis and characterization
The compounds  LPSF–GQ-147 (Z)-5- (4-
chlorobenzylidene)-3-(3,4-dichlorobenzyl) thiazolidine-
2,4-dione (Figure 1, no. 5) and LPSF–CR-35 (Z)-3-(4-
bromobenzyl)-5-(3-bromobenzylidene) thiazolidine-
2,4-dione (Figure 1, no. 10) were obtained from 
Laboratório de Planejamento de Síntese de Fármacos at 
the Universidade Federal de Pernambuco in Pernambuco, 
Brazil, and were duly identified by the nuclear magnetic 
resonance of hydrogen as well as infrared (IR) and mass 
spectroscopy (MS). Figure 1 displays the synthetic 
route of both compounds. To synthesize LPSF–GQ-147, 
published chemical data regarding 3-(3,4-dichlorobenzyl) 
thiazolidine-2,4-dione (LPSF–GQ-142; Figure 1, no. 3; 
Bozdağ–Dündar et al., 2006) were used (not shown). 
Next, 1.0 eq of 3-(3,4-dichlorobenzyl) thiazolidine-2,4-
dione LPSF–GQ-142 (Figure 1, no. 3) and 1.0 eq of 
(Z)-ethyl 2-amino-3-(4-chlorophenyl) acrylate LPSF–IP-4 
(Figure 1, no. 4) were refluxed in ethanol in the presence 
of piperidine and heated at 55 °C for 3 h. Afterward, the 
mixture was filtered and washed with water. White solid. 
C17H10Cl3NO2S. Mp: 156–7 °C. Yield: 71%. IR (KBr, 
cm-1): 1,682 (C=O), 1,738 (C=O), 1,619 (C=C), 1,339 
(C–N). H1 NMR (300 MHz, DMSOd6) δ 7.97 (s, 1H, 
=CH), 7.68–7.60 (m, 6H, 3-Ar–H, 5, 6 pos., 5-Ar–H, 2, 3, 
5, 6 pos.), 7.32 (s, 1H, 3-Ar–H, 2 pos.), 4.84 (s, 2H, CH2).
Obtaining LPSF–CR-35 (Figure 1, no. 10) began by 
reacting thiazolidine-2,4-dione (Figure 1, no. 1), which 
was reacted with 1-bromo-4-(chloromethyl) benzene 
(Figure 1, no. 6) under basic conditions to obtain the 
intermediate 3-(4-bromobenzyl) thiazolidine-2,4-dione 
(Figure 1, no. 7) following the procedure of Brandao 
et al. (2004). Next, 2-cyano-3-(4-chlorophenyl)-acrylic 
acid ethyl ester (Figure 1, no. 4; Mourão et al., 2005) 
was synthesized through Knoevenagel condensation 
between 4-chlorobenzaldehyde and ethyl cyanoacetate. 
A Michael addition was performed by reacting the (E)-3-
(3-bromophenyl)-2-ethoxyacrylonitrile (Figure 1, no. 9) 
with the intermediate 3-(4-bromobenzyl) thiazolidine-2,4-
dione (Figure 1, no. 7) to form the final compound LPSF–
CR-35 (Figure 1, no. 10) Reactions were monitored with 
analytical thin-layer chromatography in 60 F254 silica 
gel plates and visualized under ultraviolet light (254 nm). 
Melting points were determined with a Quimis 340 
capillary melting point apparatus and were not corrected. 
Infrared spectra were recorded as KBr discs using a Bruker 
(IFS66) infrared spectrophotometer. 1H nuclear magnetic 
resonance (NMR) spectra were recorded in a VMMRS 300 
MHz Varian spectrometer using tetramethylsilane as the 
internal standard and DMSO-d6 as the solvent. Chemical 
shifts (δ, ppm) were assigned according to the internal 
standard signal of tetramethylsilane in DMSO-d6 (δ, 
ppm). Coupling constants (J) are reported in Hz. 1H NMR 
spectra are reported in the following order: chemical shift, 
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multiplicity, number and type of proton, and coupling 
constants. Mass spectra with MALDI-TOF Autoflex III 
(Bruker Daltonics, Billerica, MA, USA). Laser Nd:YAG, 
355 nm. Freq. laser: 100 Hz. The derivative 3 (Figure 1) 
was isolated as a single isomer. X-ray crystallographic 
studies and 13C NMR have demonstrated a preferred Z 
configuration for 5-benzylidene-thiazolidinones (De 
Simone et al., 1995; Guarda et al., 2003; Handzlik et 
al., 2012; Karolak–Wojciechowska et al., 2009; Tan, 
Ang, Fong, 1986). The presence of the arylidene proton 
peak in 1H NMR for the synthesized derivative (Z)-3-(4-
bromobenzyl)-5-(3-bromobenzylidene) thiazolidine-2,4-
dione (Figure 1, no. 10) confirmed the completion of the 
nucleophilic addition reaction. The IR spectrum of the 
compound showed characteristic peaks of the carbonile 
group and arilidene. For the preparation of (Z)-3-(4-
bromobenzyl)-5-(3-bromobenzylidene) thiazolidine-
2,4-dione (Figure 1, nº 10), equimolar amounts of 
3-(4-bromobenzyl) thiazolidine-2,4-dione (Figure 1, no. 7) 
and (E)-3-(3-bromophenyl)-2-ethoxyacrylonitrile of 200 
and 165 mg, respectively, were reacted using absolute 
ethanol (8 mL) as the solvent and morpholine (1 mL) as the 
catalyst. The reaction mixture was heated to 50 °C for 8 h 
and afterward cooled to roacom temperature. The solid that 
precipitated out was filtered in a vacuum and washed with 
water and absolute ethanol. MF: C17H11Br2NO2S; MW: 
450,8877; MP: 205-6 °C; yield: 86%; Rf: 0.60 n-hexane/
ethylacetate 8:2. IR (υ, cm-1; KBr): 1,743 (C=O), 1,679 
(C=O), 1,609 (C=C). 1H NMR (300 MHZ, DMSO-d6): 
4.81 (s, 2H, CH2), 7.29 (dt, 1H, H–Ar, J = 8.7 Hz), 7.49 
(d, 2H, H–Ar, J = 7.8 Hz), 7.55 (dt, 1H, H–Ar, J = 8.8 Hz), 
7.61 (d, 1H, H–Ar, J = 7.8 Hz), 7.70 (m, 1H, H–Ar), 7.87 
(t, 1H, H–Ar, J = 1.8 Hz), 7.96 (s, 1H, -CH=). MS (m/z) 
relative intensity: expected value [M]+ 450.887, found 
value (M+H)+1 451.785.
Cell collection
Spleen
The spleens of 30-d-old male mice BALB/c 
(n = 5) were obtained and maintained in the Laboratory 
of Immunopathology Keizo Asami (UFPE) following 
the recommendations of the Ethics Committee on 
Experimental Animal Research of UFPE.
Each spleen was aseptically removed and placed in 
a Petri dish containing RPMI-1640 (Gibco). In a vertical 
flow, each spleen was transferred to another Petri dish 
and washed in RPMI-1640 medium. The cell suspension 
obtained from each spleen was filtered in a 40-μm 
nylon cell strainer (BD FalconTM) and transferred to 
conical centrifuge tubes (Falcon). The splenocytes were 
centrifuged with RBC lysis buffer 1× (eBiosciences) 
for incubation and resuspended on RPMI-1640 (Sigma) 
medium supplemented with 10% fetal bovine serum, 
10 mM of 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic 
acid (Gibco), and 200 U/mL of penicillin–streptomycin 
(Gibco). Cell viability was determined by using trypan 
blue exclusion with 0.4% trypan blue (Sigma); samples 
were used only when viability exceeded 98%.
Peripheral blood mononuclear cells (PBMCs)
PBMCs were isolated from the blood of healthy 
donors (n = 15) aged 6–17 years old and asthmatic 
patients, following their informed consent to participate in 
the study. The recruitment of those patients was conducted 
at the Division of Pediatric Allergy at the Hospital das 
Clínicas at UFPE. Forty-two participants 6–20 years old 
had been diagnosed with moderate (n = 27) or severe 
(n = 15) persistent asthma according to the Global 
Initiative for Asthma (2009). Patients who presented with 
FIGURE 1 - Synthetic route for compounds LPSF/GQ-147 (Z)-5-(4-chlorobenzylidene)-3-(3,4-dichlorobenzyl) thiazolidine-2,4-
dione (nº 5) and LPSF/CR-35 (Z)-3-(4-bromobenzyl)-5-(3-bromobenzylidene) thiazolidine-2,4-dione (nº 10).
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atopic dermatitis, history of food allergy, autoimmune 
disease, immunodeficiency, infection, or cancer were 
excluded. The most revelant clinical and laboratorial 
parameters are presented in Table I.
PBMCs were obtained by centrifugation with a 
Ficoll–PaqueTM Plus (GE Healthcare Bio-Sciences) 
centrifuge with a density 1.077 g/mL and resuspended in 
RPMI 1640 medium (Gibco) supplemented with 10% fetal 
bovine serum (Gibco), 10 mM of 4-(2-hydroxyethyl)-1-
piperazine-ethanesulfonic acid (Gibco), and 200 U/mL 
of penicillin–streptomycin (Gibco). Cell viability was 
again determined by using trypan blue exclusion with 
0.4% trypan blue (Sigma); samples were used only 
when viability exceeded 98%. For the assays, PBMCs 
(1 × 106 cells/mL) were stimulated or not with phorbol 
12-myristate 13-acetate (PMA) + ionomycin and 
incubated for 48 h before treatment with LPSF–CR-35 at 
10 µM and 100 µM. Methylprednisolone was used as a 
positive control. 
Cytotoxicity assay
Mice splenocytes and the PBMCs of healthy donors 
were incubated in the presence of compounds in different 
concentrations: 100 and 250 µM for the splenocytes and 10 
and 100 µM for the PBMCs. Cytotoxicity was quantified 
in terms of the ability of living cells to reduce (3-(4,5) 
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) to an insoluble colored formazan derivative. After 
48 h in a 5% CO2 air-humidified atmosphere at 37 °C, 20 μL 
of MTT solution (0.5 mg/mL of phenol red-free RPMI 
medium) was added. After incubation for another 3 h, the 
formed crystals were dissolved in 20% SDS, and absorbance 
intensity was measured by a microplate reader (BioTek 
EL808®) at 570 nm. All experiments were performed in 
triplicate, and relative cell viability (%) was expressed as a 
percentage relative to the vehicle-treated cells. 
Cytokine titration
Cytokines present in culture supernatants were 
quantified by sandwich enzyme-linked immunosorbent 
assay (ELISA) according to the procedure recommended 
by the suppliers.  The lower detection l imits of 
IL-6, IL-17A, IL-22, and IFNγ were 9.375 pg/mL, 
15.625 pg/mL, 31.25 pg/mL and 15.625 pg/mL, 
respectively. Cytokines in the supernatants of splenocyte 
cultures were assayed with ELISA mouse kits according to 
the manufacturer’s instructions. The lower detection limits 
were 7.8 pg/mL for IL-6 (BD Biosciences) and IL-22 
(eBiosciences), 3.9 pg/mL for IL-17A (eBiosciences), and 
15.6 pg/mL for IFNγ (BD Biosciences).
Quantitative real-time polymerase chain reaction
To gauge the ability of the compounds to modulate 
PPARγ gene expression, PBMCs were used as models (Da 
Rocha Junior et al., 2013). Total RNA from the healthy 
cells was extracted using Trizol® (Life Technologies) 
in accordance with the manufacturer’s instructions, 
and cDNA synthesis was achieved with 3–4 µg of total 
RNA using the High Capacity Archive kit (Applied 
Biosystems). PPARγ mRNA levels were measured by 
real-time polymerase chain reaction (RT-PCR) using the 
18S ribosomal gene as the internal standard. Standard 
TaqMan probes were Hs01115513_m1 for PPARγ 
and Hs03928990_g1 for 18S amplification. RT-PCR 
reactions were performed using an ABIPrism 7900HT 
sequence detection PCR machine (Applied Biosystems) 
according to the manufacturer’s instructions. Relative 
gene expression was calculated by using the 2-ΔΔCT method.
Ethics
The Animal Ethics Committee at the Biological 
Science Center at UFPE approved the experiments 
TABLE I - Demographic, clinical and laboratory data of asthma 
patients
ASTHMA CONTROLS
Number of patients 42 34
Age (years) 
     Mean (range)
12.7 
8-21
11.7 
6-17
Sex 
     Female 
     Male
 
17 
25
 
16 
18
Classification 
     SPA 
     MPA 
FEV1 % predicted 
 
IgE level (ng mL-1 )1 
Allergen-Specific IgE 
     Positive 
     Negative 
ACT Score
 
15 
27 
SA:75.5 
MPA:88.0 
1347 
 
29 
13 
SPA: 15.57 
MPA:12
FEV, forced expiratory volume; ACT, Asthma Control Test; 
SPA, severe persistent asthma; MPA, Moderate persistent 
asthma.
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(no. 23076.025821/2013-01). Written informed consent 
was obtained from all participants or their parents. The 
study was approved by the Research with Humans 
Ethics Committee of the Health Science Center at UFPE 
(no. 479/10). 
Statistical analysis
Results were analyzed using the nonparametric 
Wilcoxon matched pairs test; p values exceeding .05 were 
deemed significant for PBMCs. The Mann–Whitney test 
was used to assess cytokines in mice splenocytes. All 
data were plotted and analyzed with GraphPad Prism 5.0 
software. In all graphs, bars represent M ± SD. 
RESULTS
Toxicity
The non-toxic dose of LPSF–CR-35 was determined 
before anti-inflammatory properties were evaluated in 
PBMCs and splenocytes. For splenocytes, LPSF–CR-35 
presented 91.4% (±5.07) viability after treatment with 
100 µM and 78% (±6.4) viability after treatment with 
250 µM. In PBMCs from healthy donors, cytotoxicity 
was also low, with 97.9% (±3.35) viability at 10 µM 
and 91.2% (±4.2) viability at 100 µM. Afterward, 
LPSF‑CR-35 anti-inflammatory activity in splenocytes at 
10 and 100 µM was screened by using a dose of 250 µM; 
samples with cell viability exceeding 20% were not used 
in subsequent experiments.
Anti-inflammatory screening of splenocyte 
cultures
Prior to using the newly synthesized compounds in 
PBMCs from asthmatic participants, splenocytes were 
screened to evaluate the possible immunomodulatory 
effect of LPSF–CR-35 by using concanavalin A (ConA) 
as the cell mitogen. Dose-response behavior occurred 
during IFNγ (Figure 2A), IL-6 (Figure 2B), and IL-17A 
(Figure 2C) secretion when the cells were treated 
FIGURE 2 - Evaluation of pro-inflammatory cytokines release inhibition by LPSF/CR-35 and LPSF/GQ-147 in BALB/c mice 
splenocytes culture (n=5). IFNγ (A, B); IL6 (C, D); IL17 (E,F). UC = untreated cells; ConA = concanavalin A. 
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with LPSF–CR-35 at 1, 10, and 100 µM. In relation 
to ConA-treated cells, despite a marked reduction to 
cytokine levels, particularly at 100 µM, no difference was 
significant. Similarly, the treatment of the culture medium 
with LPSF–GQ-147 decreased the levels of IFNγ by 
threefold in relation to ConA-treated cells; the reduction 
was greater at 100 µM (Figure 2D). For IL-6, the reduction 
level was by approximately 2.5-fold and greater at 100 µM 
(Figure 2E). By contrast, a dose response curve emerged 
for IL-17; cytokine levels were reduced by 3.5-fold at 
100 µM (Figure 2F). There were no statistically significant 
results for the cytokine levels investigated.
Because both compounds inhibited proinflammatory 
cytokine levels in splenocytes, the new compounds were 
tested in PBMCs from pediatric asthmatic patients at 10 
and 100 µM, both of which showed the best responses to 
splenocyte screening.
Cytokine modulation by LPSF–CR-35 and  
LPSF–GQ-147 in PBMCs of asthmatic participants
On a culture medium of PBMCs treated with 
LPSF–CR-35, levels of IFNγ significantly reduced at 
10 µM (p = .032) and 100 µM (p = .02) when compared to 
levels in the PMA–ionomycin condition (Figure 3A). By 
contrast, the reduction of IL-6 levels was significant only 
at 100 µM (p = .02), as shown in Figure 3B. For IL-17A, 
the reduction induced by LPSF–CR-35 was significant 
at 10 µM (p = .039) and became even more significant 
at 100 µM (p = .015), as shown in Figure 3C. For IL-22, 
FIGURE 3 - Evaluation of pro-inflammatory cytokines release inhibition by LPSF/GQ-147 in PBMC culture from children asthmatic 
patients. IFNγ (A, B); IL-6 (C, D); IL-17A (E, F); IL-22 (G, H). PI = PMA + Ionomycin; MP = methylprednisolone. (*p<0.05 and 
*p<0.01).
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the reduction by LPSF–CR-35 was significant at 100 µM 
(p = .039) only (Figure 3D). Unlike LPSF–CR-35, 
LPSF‑GQ-147 did not decrease IFNγ (Figure 3E), IL-6 
(Figure 3F), IL-17 (Figure 3G), or IL-22 (Figure 3H) 
secretion in PBMCs from asthmatic participants.
Modulation of PPARγ mRNA expression by  
LPSF–GQ-147
PPARγ expression was evaluated in human PBMCs 
from healthy individuals for 12 h in the absence or 
presence of the agonist rosiglitazone (100 µM) as the 
positive control or LPSF–GQ-147 (100 µM). As shown 
in Figure 4A, both treatments induced PPARγ expression 
in PBMCs, although LPSF–GQ-147 resulted in a greater 
increase in expression (p = .0828).
The in vitro ability of PMA, used as a standard 
stimulus, and ionomycin to directly affect PPARγ 
expression in the absence or presence of PPARγ 
agonists was also analyzed. As shown in Figure 4B, 
LPSF–GQ-147 significantly reduced PPARγ expression in 
PMA–ionomycin-induced cytokine secretion in PBMCs 
(p = .03), as did rosiglitazone (p = .01).
DISCUSSION
Asthma is characterized by the overproduction of 
cytokines such as IL-17A and IL-22, released by Th17 
lymphocytes differentiated by IL-6 and TGF-β induction 
(Ivanov et al., 2006), as has been extensively studied 
in pursuit of new anti-inflammatory drugs. The study 
presented here described a new TZD able to decrease 
levels of IL-17A, IL-6, and IFN-γ in vitro and levels of 
IL-22 more effectively than methylprednisone.
The TZD ring is responsible for many pharmacological 
effects, including antitumor and anti-inflammatory ones 
(Faine et al., 2011). In inflammatory diseases, the ring 
acts as a PPARγ agonist, whose activation allows the 
reduction in the synthesis and release of immunomodulatory 
cytokines from many cells related to airway inflammation, 
airway remodeling, and airway hyper-responsiveness (Shen 
et al., 2012; Zenhom et al., 2011). 
In addition to its anti-inflammatory role, the TZD 
ring allows the introduction of many substituents, which 
recommends its use as a framework for developing novel 
compounds (Shen et al., 2012). In LPSF–CR-35, the 
substituent bromobenzylidene may increase the anti-
inflammatory action given its high electronegativity that 
allows stronger binding with the PPARγ receptor. 
Dai et al. (2011) observed similar behavior in 
the presence of chlorobenzylidene in andrographolide 
derivatives, since both molecules presented similar 
electronegativity. Although the present study involved in 
vitro analyses only, Iwakura et al. (2011) demonstrated 
that, in a murine model, PPARγ agonists suppress IL-17 
expression in the lungs, which suggests that LPSF/GQ-147 
would present the same behavior in in vivo models; 
however, more data are needed to confirm that hypothesis. 
PPAR agonists may therefore be useful in treating 
inflammatory lung diseases, which should prompt 
increased interest in the receptors and the study of their 
role in within-airway allergic diseases (Asaka et al., 2011).
Among other results, a major reduction was 
observed in IL-17A levels, in which the concentration of 
FIGURE 4 - PPARγ18s mRNA ratio in PBMCs from healthy individuals. A. PPARγ mRNA in cells treated with Rosiglitazone 
and LPSF/GQ-147 compound at concentration of 100 µM. B. Iono and PMA enhance PPARγ expression and its agonists reduce 
significantly PPARγ mRNA antagonizing the effects of Iono and PMA (*p<0.05).
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100 µM LPSF–CR-35 reduced the cytokines in the cells 
of asthmatic participants. That observation is interesting, 
because IL-17 has been strongly linked to chronicity in 
lung diseases, in which it stimulates innate immunity 
and induces neutrophilic airway inflammation, chiefly by 
stimulating immunoglobulin E production by human B 
cells mediated by IL-17A (Zenewicz et al., 2008). 
The role of IL-22 in inflammatory diseases can be 
either pathological or tissue protective depending on the 
disease. Sonnenberg et al. (2010) demonstrated that IL-
17A can govern the proinflammatory–pathological versus 
tissue-protective properties of IL-22 in the lungs. They 
suggested that the presence of IL-17A is necessary for 
the proinflammatory role of IL-22 amid airway damage 
and inflammation, in which both ILs act synergistically 
by promoting chemokine expression and neutrophil 
recruitment. In addition, Liang et al. (2007) found that 
the administration of exogenous IL-22 was insufficient to 
promote neutrophil recruitment to the airway. Together, 
the studies suggest that LPSF–CR-35 could be used as 
an anti-inflammatory drug in asthma, because the newly 
developed TZD more effectively reduced the expression 
of both cytokines than methylprednisone. 
IL-6 is an important regulator of CD4+ T cell 
differentiation that inhibits Th1 differentiation and promotes 
Th17 cell differentiation (Dienz, Rincon, 2009) and has 
thus been described as an inflammation marker in diseases 
such as rheumatoid arthritis and asthma (Kishimoto, 2010). 
Recently, IL-6 was described as not only an inflammatory 
marker but also an active cytokine, and some studies have 
described a correlation between the presence of IL-6 in 
airways and impaired lung function, thereby suggesting 
its direct involvement in the pathogenesis and progression 
of the disease (Morjaria et al., 2011; Neveu et al., 2011). 
Because IL-6 is a potential target in asthma treatment, our 
results reinforce the importance of the newly developed 
TZD CR-35 as an anti-inflammatory agent.
The reduction of IL-17A, IL-6, IL-22, and IFN-γ 
levels in asthmatic participants presented by LPSF‑CR-35 
confirms the anti-inflammatory role of the TZD in 
association with the bromobenzylidene substituent in 
different actions in the inflammatory pathway and highlights 
the importance of the newly developed TZD as a potential 
anti-inflammatory drug.
Interestingly, the compound was more effective at 
reducing IL-17A than IL-6, IL-22, and IFNγ cytokines 
(Diehl, Rincón, 2002; Kumar et al., 2012). The reduction 
in IL-17A is important because research on mice has 
shown that IL-17 could trigger lung inflammation by 
stimulating innate immunity and induce neutrophilic 
airway inflammation, which are strongly linked to chronic 
inflammation (Iwakura et al., 2011).
Results show that LPSF–GQ-147 enhanced 
PPARγ expression in the absence of a stimulus. Palma 
(2012) found that the agonists 15d-PGJ, MTX, and 
methylprednisolone increased receptor expression in 
cells isolated from healthy donors (Palma et al., 2012). 
Earlier, Marx et al. (1998) observed that PMA–ionomycin 
enhanced PPARγ expression and that its agonists 
significantly reduced PPARγ mRNA, thereby possibly 
antagonizing the effects of PMA–ionomycin mitogens. 
PPARγ mRNA expression in U937 cells also increased 
during PMA-induced differentiation (Marx et al., 1998).
In addition to the intrinsic anti-inflammatory activity 
of the thiazolidine ring, the substituent chlorobenzylidene, 
present in LPSF–GQ-147, potentiates anti-inflammatory 
activity when introduced in some molecules (Dai et al., 
2011), which partly explains the action of the molecule 
examined in the present study. Moreover, the other 
substituent from the molecule, dichlorobenzyl, appears 
in DG-041 as an antagonist from the EP3 receptor, which 
is the natural agonist of the inflammatory mediator 
prostaglandin E2 (Heptinstall et al., 2008).
CONCLUSIONS
These results present the newly developed TZD 
LPSF–CR-35 reduced the secretion of IL-17A, IL-22, 
IL-6, and IFNγ in PBMCs from asthmatic children and 
that LPSF–GQ-147 modulated PPAR mRNA levels. Such 
findings indicate that both compounds are promising 
candidates for drugs to treat inflammation and asthma.
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